Lv41
530 积分 2023-01-29 加入
PD1 agonist antibody passes first phase II trial for autoimmune disease
1小时前
已完结
Tregs in allogeneic hematopoietic stem cell transplantation (allo-HSCT): Suppressing GVHD While Preserving GVL
30天前
已完结
Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies
30天前
已完结
Inhibitory PD-1 axis maintains high-avidity stem-like CD8(+) T cells
2个月前
已完结
Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy
2个月前
已完结
Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers
2个月前
已关闭
PT101: A Treg selective agonist IL-2 mutein therapy for autoimmunity
2个月前
已关闭
Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers
2个月前
已关闭
PT101: A Treg selective agonist IL-2 mutein therapy for autoimmunity
2个月前
已关闭
Abstract 3500: LBL-054-CD3: An anti-CDH17 and CD3 bispecific antibody for the treatment of CDH17-positive gastrointestinal cancer
2个月前
已完结
皖公网安备34019202002308
